Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06824103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion moved earlier from Nov 29, 2029 to May 10, 2029 Site details revised at 1 of 22 sitesv8 Show 1 more changeShow less
    • Site details revised at 1 of 22 sites
  2. Study sites: 19 to 22 Completion date: Jan 11, 2032 to May 23, 2031v7 Show 1 more changeShow less
    • Completion date: Jan 11, 2032 to May 23, 2031
  3. Study sites: 14 to 19v6
  4. Study sites: 9 to 14v5
  5. Study sites: 3 to 9v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 3 · Start date changed from estimate of Nov 21, 2025 to Sep 9, 2025v3 Show 2 more changesShow less
    • Study sites: 1 to 3
    • Start date changed from estimate of Nov 21, 2025 to Sep 9, 2025
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).
Trial Details
NCT Number NCT06824103
Lead Sponsor Novartis Pharmaceuticals
Conditions Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov